GO
Loading...

Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Medicine

More

  • Big Pharma At 30,000 Feet Monday, 6 Apr 2009 | 8:58 AM ET
    Pills

    I don't want to get anyone in trouble, so I won't name the company, the drug or even what it's for. (Note to corporate PR folks reading this: Don't even try to pry it out of me. My lips are sealed.) All I'll say is that it's one of the biggies.

  • Dendreon's Freaky Friday Friday, 3 Apr 2009 | 4:08 PM ET
    dendreon_logo_new2.jpg

    I'm not really enjoying my "day off" so far here in rather gloomy, cool L.A. as I've been kept pretty busy trying to chase down the Dendreon story.

  • It's Diabetes Drug Days Wednesday, 1 Apr 2009 | 11:28 AM ET
    Pills

    An estimated 20 million or so Americans have the disease, which many experts call an epidemic. It costs this country tens of billions of dollars a year to deal with it. And several biopharma and monitoring device companies are racing to grab a bigger piece of this fast-growing, sugar-free pie.

  • Top Doctors Take Stand Against Pharma Marketing 'Swag' Tuesday, 31 Mar 2009 | 4:02 PM ET

    A prestigious peer-reviewed journal is proposing taking a hardline stance on what it calls the "pervasive" funding relationship between drug and medical device companies and professional medical associations.

  • Lilly & Amylin: Please Keep It Simple Tuesday, 31 Mar 2009 | 12:46 PM ET

    Shares of Amylin Pharmaceuticals are rallying on a press release from AMLN and its partners Eli Lilly and Alkermes that their once-a-week version of the injectable diabetes drug Byetta (buy-ate-uh) lowered blood sugar levels more than the pills Januvia from Merck and Actos from Takeda.

  • Novartis Drug Approved as Kidney Cancer Treatment Monday, 30 Mar 2009 | 6:09 PM ET

    A drug from Novartis has won U.S. approval as a treatment for patients with kidney cancer that has returned after treatment with older drugs.

  • Knocked Out Of The Arena Monday, 30 Mar 2009 | 11:27 AM ET
    arena_pharm.jpg

    There is no quid pro quo in my line of work. At least there shouldn't be. But when you do two stories on CNBC and another one on "TODAY" that mentions a company's drug and profiles a patient who appears to have been a "responder" in one of its clinical trials you expect a certain basic professional level of cooperation and assistance.

  • Genentech, Dendreon & Your Emails Friday, 27 Mar 2009 | 4:24 PM ET

    I'm on the road on assignment, but used a little downtime to go through the "Pharma's Market" mailbox. Regarding my farewell to Genentech post yesterday a couple of folks emailed to point out that GENE was Genentech's ticker symbol when it was traded on the Nasdaq back in the day. Then it was GNE on the NYSE before going to the much better DNA.

  • Goodbye Genentech & Your DNA Thursday, 26 Mar 2009 | 2:29 PM ET
    genetech_logo_new.jpg

    DNA has always been one of my favorite clever ticker symbols on the biopharma beat. Sure, GENE might've made sense for Genentech if it had been listed on the Nasdaq, but DNA was pretty good. But after today DNA is no more.

  • Did Dendreon Do Itself In? Wednesday, 25 Mar 2009 | 12:34 PM ET
    dendreon.jpg

    Oh, the Dendreon investor message boards are on fire! And my inbox has a few sparks. Matthew Herper at Forbes wrote a piece today daring to question the integrity of the all-important data due out sometime next month on DNDN's prostate cancer treatment Provenge.

  • Roll Out The Red Carpet! ASCO Goes Hollywood Tuesday, 24 Mar 2009 | 10:45 AM ET
    asco_new_logo.jpg

    All of my, ahem, complaining and whining, to put it politely, about the American Society of Clinical Oncology may not have fallen on deaf ears after all.

  • Genentech & Abbott CEOs Roar Monday, 23 Mar 2009 | 3:47 PM ET
    Genetech

    Art Levinson and Miles White are "Kings of the Jungle." At least Barron's thinks they are. The weekly investment periodical picked the pair as the only two from biopharma to make its annual list of the "30 Most Respected CEOs."

  • My Tweets And Your Emails Friday, 20 Mar 2009 | 4:44 PM ET

    My first week on Twitter has gone pretty well. Despite some Twitter trouble (or should that be twubble?) with website capacity, I've picked up more than 75 followers already.

  • GlaxoSmithKline's New Ally For Alli Friday, 20 Mar 2009 | 11:28 AM ET
    alli_logo.jpg

    Normally, the folks at GlaxoSmithKline keep us tightly in the loop when there's news. So, I'm a bit surprised that it took a "tweet" on Twitter this morning to learn that four days ago the company put out a press release that has "Pharma's Market" written all over it.

  • Pfizer: Turning The Bad Economy Into Good PR? Thursday, 19 Mar 2009 | 11:01 AM ET
    Pfizer

    Pfizer announced this morning that it's raising the income levels for uninsured people to qualify for cheaper or free drugs because of the bad economy.

  • NEJM Gets At Heart Of Pfizer's/Pharma's Problems Wednesday, 18 Mar 2009 | 5:15 PM ET

    Scientific and medical journals like to keep their distance from the business side of things. That's why I think it's worth noting that a "Perspective" piece--think of it as kind of a newspaper Op-Ed--in "The New England Journal of Medicine" starts by mentioning Pfizer's stock price and its recent proposed acquisition of Wyeth.

  • Sam Waksal Wants Back In Biotech Tuesday, 17 Mar 2009 | 10:55 AM ET
    Sam Waksal

    Despite my repeated invitations for his first post-jailhouse interview on this blog and through one of his contacts, Sam Waksal didn't respond. Given his Manhattan social scene background it should not, perhaps, come as a surprise that the founder of ImClone Systems decided to have his coming-out party in "New York" magazine.

  • Roche Gets Genentech, But At What Price? Monday, 16 Mar 2009 | 12:56 PM ET

    The overwhelming majority of people who have voted in the “Pharma’s Market” poll about the future of Genentech’s execs and top scientists thinks most of them will eventually bolt.

  • I Can’t Get Off Drugs Monday, 16 Mar 2009 | 11:20 AM ET
    pharma_new3.jpg

    Last week was a busy week, to say the least, on the Pharma beat - So I was looking forward to the weekend and escaping all things drug-related. But as fate would have it, it ended up being bookended by references to pharma in a couple of surprising venues.

  • Dendreon Springs Back To Life Friday, 13 Mar 2009 | 1:52 PM ET

    All of a sudden yesterday and today shares of Dendreon  —my favorite biotech story—shot up on heavy volume.